Skip to main content
Premium Trial:

Request an Annual Quote

Epitome to Develop Custom Assays for Bristol-Myers Squibb

NEW YORK, Jan. 4 (GenomeWeb News) - Epitome Biosystems said today that it has signed a technology access and product development agreement with Bristol-Myers Squibb to use its EpiTag protein-measurement platform.

 

Under the agreement, Epitome will design custom antibody arrays to measure proteins specified by Bristol-Myers Squibb to accelerate its clinical development programs. In return, Epitome will receive development funding and license fees from Bristol-Myers Squibb.

 

The EpiTag technology uses an in silico approach to identify peptide tags for any protein based on sequence information, Epitome said. The company said the platform enabled the development of multiplex protein assays.

Financial details were not discussed.

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.